<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00480402</url>
  </required_header>
  <id_info>
    <org_study_id>VLC-VS-0405-507-23</org_study_id>
    <nct_id>NCT00480402</nct_id>
  </id_info>
  <brief_title>Natural Progesterone and Preterm Birth in Twins</brief_title>
  <official_title>Eficacia de Los Suplementos de Progesterona Natural en la prevención Del Parto pretérmino Gemelar</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Valenciano de Infertilidad, IVI VALENCIA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Valenciano de Infertilidad, IVI VALENCIA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effectiveness of natural progesterone supplementation in preventing preterm&#xD;
      births in twins.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To assess the effectiveness of natural progesterone supplementation in preventing&#xD;
      preterm births in twins.&#xD;
&#xD;
      Study Design: National multicenter randomized double blind controlled clinical trial.&#xD;
&#xD;
      Setting: Six tertiary hospitals in the east of Spain (communities of Valencia and Murcia):&#xD;
      Instituto Universitario IVI Valencia, Hospital Universitario La Fe (Valencia), Hospital&#xD;
      Universitario Dr. Peset (Valencia), Hospital General Universitario (Alicante), Hospital Vega&#xD;
      Baja de Orihuela (Alicante) y Hospital Virgen de la Arrixaca (Murcia).&#xD;
&#xD;
      Population: 246 bichorionic biamniotic twin pregnant women divided in three groups according&#xD;
      to the allocated randomized treatment: (I) placebo (N=82); (II) 200 mg progesterone (N=82);&#xD;
      and (III) 400 mg progesterone (N=82).&#xD;
&#xD;
      Methods: All participant women will self-administer two vaginal pessaries at bedtime&#xD;
      containing the allocated treatment. Vaginal pessaries will be identical externally but will&#xD;
      contain either placebo or 200 mg of natural progesterone (Laboratorios Effik, Madrid, Spain).&#xD;
      The treatment will be applied from the 20th week until the 34th week (or until delivery if it&#xD;
      occurred earlier). Control visits will be performed at 24, 28, 32 and 34 weeks. Pregnancies&#xD;
      will be managed according to each local protocol. An external statistical analysis will be&#xD;
      performed on intention to treat basis.&#xD;
&#xD;
      Main outcome measure: Preterm birth rate (&lt;37 weeks). Secondary outcome measures: very&#xD;
      preterm birth rate (&lt;32 weeks); cervical length measured by vaginal ultrasound at each&#xD;
      control visit; need for tocolytic treatments; rate of preterm premature rupture of membranes;&#xD;
      and perinatal morbidity and mortality.&#xD;
&#xD;
      Estimated period of study: 2006-2008.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">290</enrollment>
  <condition>Preterm Birth</condition>
  <arm_group>
    <arm_group_label>400 mg Progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately one third of the bichorionic biamniotic twin pregnant women randomized to the 400 mg Progesterone Group vaginal pessaries arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg Progesterone Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately one third of the bichorionic biamniotic twin pregnant women randomized to the 200 mg Progesterone Group vaginal pessaries arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Approximately one third of the bichoronic biamniotic twin pregnant women were randomized to the placebo vaginal pessaries arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>200 mg of Progesterone</intervention_name>
    <description>Administration of 200 mg of Progesterone</description>
    <arm_group_label>200 mg Progesterone Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>400 mg Progesterone</intervention_name>
    <description>Administration of 400 mg Progesterone</description>
    <arm_group_label>400 mg Progesterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administration of a Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Bichorionic biamniotic twin pregnant women&#xD;
&#xD;
          -  = or &gt; 18 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Single pregnancy or monochorionic twin pregnancy or triplets&#xD;
&#xD;
          -  Chronic hepatic pathology, previous alterations in hepatic analysis during&#xD;
             anti-contraceptive treatment; or gestational cholestasis in in previous&#xD;
             pregnancies.Basal alterations in hepatic analysis profile.&#xD;
&#xD;
          -  Profylactic cerclage until week 14.&#xD;
&#xD;
          -  Basal alterations in renal analysis profile&#xD;
&#xD;
          -  Local allergy to micronized natural progesterone&#xD;
&#xD;
          -  Genital pathology not allowing for correct absorption of medication&#xD;
&#xD;
          -  Fetal anomoly diagnosed after sonograph week 12 and/or 20.&#xD;
&#xD;
          -  Smokers of more than 10 cigarettes/day&#xD;
&#xD;
          -  Consumers of illegal substances&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vicente Serra, MDPhD</last_name>
    <role>Study Director</role>
    <affiliation>Instituto Valenciano de la Infertilidad</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Valenciano de la Infertilidad</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>May 28, 2007</study_first_submitted>
  <study_first_submitted_qc>May 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2007</study_first_posted>
  <last_update_submitted>April 3, 2013</last_update_submitted>
  <last_update_submitted_qc>April 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2013</last_update_posted>
  <keyword>preterm birth</keyword>
  <keyword>progesterone</keyword>
  <keyword>twins</keyword>
  <keyword>Preterm birth in twin gestations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

